Feed HAE
HA

Haemonetics HAE · NYSE

$118.76 +0.41% (+$0.48)

Market cap
$5.40B
Enterprise value
$6.35B
P/E
56.1x
Forward P/E
21.4x
PEG
0.8x
P/S
4.0x
P/FCF
18.6x
EV/EBITDA
24.3x
ROIC
8.6%
Gross margin
57.4%
Net margin
7.1%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
3.6x
Beta
0.54
Free float
98.7%

About the company

Haemonetics Corporation is an American company specializing in the development and manufacturing of medical technologies focused on blood product processing. Founded in 1971, the company’s primary focus is on innovations in blood transfusion, blood component separation, and patient monitoring. Haemonetics provides products and solutions for hospitals, blood banks, and transfusion centers that help optimize the processes of blood donation and usage, while ensuring safety and treatment efficiency. The company is known for its advanced devices and systems for separating plasma, red blood cells, and platelets, ensuring precision and quality in handling blood products.

Sector

Healthcare

Industry

Medical - Devices

CEO

Christopher A. Simon

Employees

3,009

Headquarters

Boston

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.